UACA Antibody (UACA/1222)

Western Blot: UACA Antibody (UACA/1222) [NBP2-44357] - A549 Cell Lysate using UACA / Nucling Monoclonal Antibody (UACA/1222)

Product Discontinued

UACA Antibody (UACA/1222) Summary

• Immunogen: Recombinant human UACA protein
• Localization: Nuclear membrane
• Marker: Nuclear Membrane Marker
• Specificity: UACA (Uveal Autoantigen with Coiled-coil domains and Ankyrin repeats) is a 1,416 amino acid nuclear membrane protein. It was originally identified as an autoantigen in patients with panuveitis, a characteristic of Vogt-Koyanagi-Harada disease, and in patients with Graves' disease. UACA was also later identified as Nucling, an mRNA differentially expressed in F9 embryonal carcinoma cells during cardiac muscle differentiation. UACA appears to function as a pro-apoptotic protein that recruits the apaf-1-pro-caspase-9 complex for the induction of apoptosis to mediate the cell-death pathway.
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: UACA
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Western Blot 0.5 - 1.0 ug/ml
• Application Notes: Optimal dilution for a specific application should be determined.
• Theoretical MW: 160 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at 4C.
• Buffer: 10 mM PBS with 0.05% BSA
• Preservative: 0.05% Sodium Azide
• Concentration: 0.2 mg/ml
• Purity: Protein A or G purified

Alternate Names for UACA Antibody (UACA/1222)

• FLJ10128
• KIAA1561MGC141969
• MGC141967
• nuclear membrane binding protein
• NUCLING
• uveal autoantigen with coiled coil domains and ankyrin repeats
• uveal autoantigen with coiled-coil domains and ankyrin repeats

Background

UACA (uveal autoantigen with coiled-coil domains and ankyrin repeats) was originally identified as an autoantigen in patients with panuveitis, a characteristic of Vogt-Koyanagi-Harada disease, and in patients with Graves' disease. UACA was also later identified as Nucling, an mRNA differentially expressed in F9 embryonal carcinoma cells during cardiac muscle differentiation. UACA appears to function as a pro-apoptotic protein that recruits the apaf-1-pro-caspase-9 complex for the induction of apoptosis to mediate the cell-death pathway.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: UACA